COMET: a multicomponent home-based disease-management programme versus routine care in severe COPD.

Area of Science:

• Pulmonology and Respiratory Medicine
• Clinical Trial Research
• Healthcare Management

Background:

• Severe Chronic Obstructive Pulmonary Disease (COPD) poses a significant burden on patients and healthcare systems.
• Effective disease management strategies are crucial for improving outcomes in severe COPD.
• The COPD Patient Management European Trial (COMET) aimed to evaluate a comprehensive home-based intervention.

Purpose of the Study:

• To investigate the efficacy and safety of a home-based COPD disease management intervention for severe COPD patients.
• To assess the impact of the intervention on hospitalisation rates, disease severity, and mortality.

Main Methods:

• An international, open-design, randomized clinical trial (RCT) involving severe COPD patients (FEV1 <50% predicted).
• Patients were randomized 1:1 to either the disease management intervention or usual care.
• The intervention included self-management, telemonitoring, care coordination, and medical management.

Main Results:

• No significant reduction in unplanned all-cause hospitalisation days per year (17.4 vs. 22.6 days).
• Significant reduction in per-protocol acute care hospitalisation days per year (p=0.047).
• Lower BODE index (p=0.01) and significantly reduced mortality rate (1.9% vs. 14.2%, p<0.001) in the intervention group.

Conclusions:

• The COMET home-based disease management intervention did not meet its primary endpoint of reducing all-cause hospitalisation days.
• The intervention demonstrated significant benefits by reducing acute care hospitalisations and mortality in severe COPD patients.
• Substantial variation in patient profiles and hospitalisation practices across countries highlights the need for tailored approaches.